July, 2025
July 2025
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
28293031  
Kevin Harrington: STING Agonist Therapy with Ulevostinag – From ESMO 2018 to Print
Jul 10, 2025, 13:47

Kevin Harrington: STING Agonist Therapy with Ulevostinag – From ESMO 2018 to Print

Kevin Harrington, Professor in Biological Cancer Therapies at Institute of Cancer Research, shared a post on LinkedIn:

“Delighted to announce the publication of this paper in Clinical Cancer Research. The paper reports on two trials of intratumoural cyclic dinucleotide STING agonist therapy with Ulevostinag (MK1454) in patients with a variety of solid cancers and lymphoma. The preliminary data were first presented at ESMO in 2018; so, it has been a long road to get it into print.

Although this paper deals largely with treatment-related toxicity and the pharmacokinetic and pharmacodynamic effects of MK1454, it is important to recognise that there are still surviving patients who entered these protocols up to 7 years ago. We hope to report on the outcome data in a follow-on paper led by the co-authors of this study.

Especial thanks go to friends and colleagues at Merck who persevered in getting the data assembled, cleaned and analysed and to all of the study teams who brought this treatment opportunity to patients under their care. Above all, grateful thanks to the patients who agreed to receive this treatment and to their families and carers who supported them through the trial.”

Title: Phase 1 and 2 Clinical Studies of the STING Agonist Ulevostinag With and Without Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors or Lymphomas

Authors: Kevin J Harrington, Stephane Champiat, Joshua D Brody, Byoung Chul Cho, Emanuela Romano, Talia Golan, John R Hyngstrom, James Strauss, David Y Oh, Aron Popovtzer, Carlos Gomez-Roca, Ruth Perets, Sung-Bae Kim, Deborah J Wong, Steven F Powell, Anuradha Khilnani, Thomas Jemielita, Qing Zhao, Runchen Zhao, Matthew Ingham

Read Full Article.

Ulevostinag

More posts featuring Cancer Research on OncoDaily.